Finding Suggests Immune System Mounts Robust Response To An Opportunistic Infection After Aggressive HIV Therapy

August 03, 1998

UC San Francisco researchers are reporting results that suggest the immune system of HIV patients mounts a robust response to at least one opportunistic infection following aggressive HIV drug therapy.

The finding, reported in the August issue of Nature Medicine, focused specifically on cytomegalovirus (CMV), the leading cause of blindness in people with AIDS.

However, said the researchers, the study may help to clarify an ongoing question in HIV treatment: Do the CD4+ T cells that are replenished by the immune system after highly active antiretroviral therapy (HAART) create the pathogen-specific responses needed to combat the opportunistic infections that afflict people with AIDS, including pneumocystis pneumonia? Each pathogen requires an individualized type of response by CD4+ T cells, which are key cells of the immune system. They are also the cells ravaged by HIV.

"CD4+ T-cell counts go up after therapy, but there is conflicting evidence as to whether the quality of the immune response is sufficient to enable patients to withstand opportunistic infections," said Joseph M. McCune, MD, PhD, an associate professor of medicine at UCSF and associate investigator at the Gladstone Institute of Virology and Immunology, which is affiliated with UCSF. "This study suggests that immune reconstitution may occur, at least in the case of responses against CMV."

The improved survival rates of people treated with aggressive HIV therapy have been attributed in part to the fact that patients are now started on therapy while their CD4+ counts are still high, and they are therefore able to mount a strong immune response, and in part to the fact that physicians are more adept at treating them.

Whether HAART plays a role in reducing opportunistic infections has been a puzzle. In February, another group of UCSF researchers reported a dramatic decline in several common opportunistic infections in HIV+ patients at San Francisco General Hospital. While they suspected the critical factor might be a reconstituted immune system after therapy, they said further studies need to be done to tease out the explanation.

In the current study, the UCSF researchers examined three groups of HIV patients. One group had an average CD4+ T cell count of 28 cells per microliter, putting them well below the level at which patients are diagnosed as having AIDS (less than 200 cells per microliter) and had active CMV disease.

This group had previously received ganciclovir, which is used to combat CMV. Another group had CD4+ T cell counts ranging from 10 to 1,000 cells per microliter after treatment with HAART, and had never had CMV disease. A third group had previously had CMV disease, but after treatment with HAART and ganciclovir these people had CD4+ T cell counts averaging 225 cells per microliter and quiescent CMV disease.

Using a relatively new technique that detects CMV-specific CD4+ T cells, the researchers determined that the patients with active CMV had low levels of these special CD4+ T cells, while patients who had never had the disease or had dormant disease had high levels of them.

"We've found a correlation between the absence of disease and the presence of CD4+ T cells that specifically respond to CMV," said McCune.

To prove the correlation, he said, would require tracing the progress of a single group of HIV+ patients with low CD4+ T cell counts and active CMV through HAART therapy to see whether they then developed CMV-antigen-specific CD4+ T cell responses and dormant CMV.

"Statistically, our data look pretty good," said McCune, "but the prospective study needs to be done."

The UCSF team plans to analyze immune responses against other pathogens that cause opportunistic infections in people with AIDS, said McCune.

The UCSF research was supported in part by grants from the University of California-wide AIDS research program and the National Institutes of Health.
-end-


University of California - San Francisco

Related Immune System Articles from Brightsurf:

How the immune system remembers viruses
For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen.

How does the immune system develop in the first days of life?
Researchers highlight the anti-inflammatory response taking place after birth and designed to shield the newborn from infection.

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.

Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.

COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.

Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.

Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.

Read More: Immune System News and Immune System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.